A see-through brain is lit up white with colored lights behind it on a black background

Light and sound stimulation improves early Alzheimer’s disease symptoms

Spending an hour every day listening to a low-pitched thrum and gazing at blinking lights may help prevent structural changes in the brain and cognitive impairments associated with Alzheimer’s disease.
Stephanie DeMarco, PhD Headshot
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

In a new medRxiv preprint, scientists from the Massachusetts Institute of Technology (MIT) reported that stimulating the brain with 40 Hz of pulsing lights and sounds was safe and reduced early signs of structural brain changes associated with Alzheimer’s disease progression. Patients with mild signs of Alzheimer’s disease also developed more stable circadian rhythms and performed better on cognitive tests during the three-month long clinical trial.

“This is just the beginning, and these are very encouraging results,” said Sylvain Williams, a neuroscientist at McGill University, who was not involved in the study.

The treatment works by modifying gamma oscillations, which are waves of electrical activity in the brain associated with higher cognitive functions like attention and memory. Alzheimer’s disease patients often have disrupted gamma oscillations. Previously, the same team of MIT researchers, led by Li-Huei Tsai, showed that they could increase gamma oscillations in the brain of a mouse model of Alzheimer’s disease by stimulating the brain with sound and light at 40 pulses per second using a device called Gamma Entrainment Using Sensory Stimuli (GENUS). Treatment with the GENUS device reduced levels of amyloid beta plaques in the mouse brains and improved their memory.

While the results of GENUS treatment looked promising in mice, scientists did not know if the same technique could work in humans until now.

Tsai’s team tested the safety and efficacy of GENUS in humans in two different clinical trials. They found that GENUS successfully induced 40 Hz gamma oscillations in cognitively normal young adults, older adults, and patients with mild dementia associated with Alzheimer’s disease. None of the groups experienced any adverse side effects from the treatment, including two additional patients with epilepsy.

“They've shown that their method actually works in humans in terms of getting the brain to oscillate at 40 Hz,” Williams said.

To test the effectiveness of GENUS in Alzheimer’s disease patients, the team performed a randomized, placebo-controlled clinical trial with patients with probable mild Alzheimer’s disease. Eight patients received the light and sound stimulation at 40Hz treatment, and seven listened to white noise and watched constant white light in the control condition.

After three months of daily use, the brains of the people in the treatment group showed less ventricular enlargement, a hallmark of Alzheimer’s disease progression, and their hippocampus volumes remained unchanged. Using fMRI, the team also found increased connectivity in brain circuits important for sensory processing and memory in the GENUS-treated patients.

Patients with Alzheimer’s disease often also have disrupted circadian rhythms, but after four months of GENUS treatment, the stability of circadian rhythms in these patients improved. And, after three months of treatment, patients showed significant improvement in a face-name association test, suggesting improved cognition.

“It is surprising to actually see some of the effects already after three months, so it is very encouraging for long term treatments,” Williams said.

While these results look promising, the team hopes to study the effectiveness of GENUS in larger and longer clinical trials soon.

“This is the first paper of a large number of papers that is going to be published on this. I know there's a lot of excitement in the field,” said Williams. “It is going to be interesting to follow this for certain. It's such a striking method.”

Reference

Chan, D. et al. Gamma Frequency Sensory Stimulation in Probable Mild Alzheimer’s Dementia Patients: Results of a Preliminary Clinical Trial. Preprint at: https://www.medrxiv.org/content/10.1101/2021.03.01.21252717v3.full-text (2021).

About the Author

  • Stephanie DeMarco, PhD Headshot

    Stephanie joined Drug Discovery News as an Assistant Editor in 2021. She earned her PhD from the University of California Los Angeles in 2019 and has written for Discover Magazine, Quanta Magazine, and the Los Angeles Times. As an assistant editor at DDN, she writes about how microbes influence health to how art can change the brain. When not writing, Stephanie enjoys tap dancing and perfecting her pasta carbonara recipe.

Related Topics

Published In

July-August Issue
Volume 17 - Issue 7 | July 2021

July/August 2021

July/August 2021 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue